Ghobrial, I M
Redd, R
Armand, P
Banwait, R
Boswell, E
Chuma, S
Huynh, D
Sacco, A
Roccaro, A M
Perilla-Glen, A
Noonan, K
MacNabb, M
Leblebjian, H
Warren, D
Henrick, P
Castillo, J J
Richardson, P G
Matous, J
Weller, E
Treon, S P
Article History
Received: 30 March 2015
Revised: 7 May 2015
Accepted: 15 May 2015
First Online: 3 July 2015
Competing interests
: Irene M Ghobrial: Consultant for Novartis, Millennium, Celgene and BMS. Philip Armand: received funding from BMS, Merck, Otsuka, Sigma Tau and Sequenta; consultant for Merck. Paul Richardson: Consultant for Novartis, Millennium and Celgene. The rest of the authors declare no conflict of interest.